MOVEMENT DISORDERS RESEARCH

Music Therapy Clinical Trial (16-2308) 

• Investigator: Isabelle Buard, PhD  
• Purpose: to learn more about the brain function related to fine motor skills in individuals with Parkinson’s disease (PD)  
• Timeline: 3-4 study visits over the course of 7 weeks and 3 sessions per week for 5 weeks for either music therapy intervention, or occupational therapy (OT) intervention, or no intervention (location options available for interventions)
• Intervention: (1) musical intervention group A, (2) musical intervention group B, (3) standard of care OT, or (4) a waitlist group for 5 weeks 
• ClinicalTrials.gov Identifier: NCT03049033  
• Key Eligibility Criteria: age 45-85 years old, diagnosis: PD, have some difficulties with fine motor skills (such as buttoning, cutting your food, or typing on a keyboard)
  

Michael J. Fox Foundation PPMI 2.0 (20-1204) 

• Investigator: Michelle Fullard, MD, MSCE  
• Purpose: to continue to obtain information from people with and without Parkinson’s disease (PD) so that researchers may better understand how PD progresses, in order to inform better treatments 
• Timeline: 2 visits annually for up to 7 years 
• ClinicalTrials.gov Identifier: NCT04477785
• Key Eligibility Criteria: age 30+ years old, diagnosis: PD for ≤ 2 years, NOT currently being treated with PD medications or expected to require PD medications within 6 months 
  

SPARX3 (20-1854) 

• Investigator: Cory Christiansen, PT, PhD 
• Purpose: to learn more about the effects of aerobic exercise on people with Parkinson’s disease (PD) who have not yet started medication for their PD  
• Intervention: moderate to high intensity exercise on a treadmill
• Timeline: exercise 4x/week with periodic study visits for 24 months  
• ClinicalTrials.gov Identifier: NCT04284436 
• Key Eligibility Criteria: age 40-80 years old, diagnosis: PD ≤ 3 years, NOT currently being treated with PD medications or expected to require PD medications within 6 months  
  

Cytokine Observational Study (18-1356)  

• Investigator:  Maureen Leehey, MD, FAAN  
• Purpose: to learn more about the level of inflammatory and other markers in the blood of patients with PD, essential tremor (ET), and healthy volunteers  
• Timeline: one time blood draw   
• Key Eligibility Criteria: age: 60-75 years old, diagnosis: PD (5-10 years since diagnosis) OR ET
  

CereGate (21-5060)

• Investigator:  Drew Kern, MD, MS 
• Purpose: to find out if CereGate therapy reduces freezing of gait in participants with Parkinson’s disease with a pre-existing Gevia™ implanted deep brain stimulation (DBS) system
• Treatment: your existing Gevia DBS system is programmed with an additional stimulation program for you to use when walking.  You continue to use your existing DBS program and existing medications.  There are no new medications, surgeries or invasive procedures.
• Timeline: 5 in person visits over approximately 100 days
• Key Eligibility Criteria: age: 21-75 years old, diagnosis: PD, currently have implanted Gevia™ DBS system, currently being treated with PD medications, currently have freezing of gait
  

ALLFTD (21-2833)

Investigator:  Peter Pressman, MD

Purpose: The ARTFL LEFFTDS Longitudinal Frontotemporal Dementia (ALLFTD) study aims to evaluate sporadic (s-) and familial (f-) frontotemporal lobar degeneration (FTLD) patients and asymptomatic family members of f-FTLD patients, characterizing the cohorts longitudinally and informing clinical trial design (Biofluid-Focused and Longitudinal arms available)

ClinicalTrials.gov Identifier: NCT04363684

ALLFTD Biofluid Timeline: one-time visit with questionnaires, neurological exam, blood drawn, and optional lumbar puncture

Biofluid Key Eligibility Criteria: diagnosis: FTLD syndrome like bvFTD, bvFTD with ALS, PPA, PSP, or CBD, age: 18+ years old

ALLFTD Longitudinal Timeline: annual visit to the clinic, each lasting 2–3 days, with questionnaires, thinking and memory questions, neurological exam, blood drawn, and an MRI

Longitudinal Key Eligibility Criteria: age: 18+ years old, diagnosis: FTLD syndrome like bvFTD, bvFTD with ALS, PPA, PSP, or CBD, OR are from a family with a mutation in a gene known tocause FTLD (such as C9orf72, MAPT, and GRN) OR have a significant family history of FTLD suggesting a familial genetic mutation

Music Therapy Clinical Trial (16-2308) 

• Investigator: Isabelle Buard, PhD 
• Purpose: to learn more about the brain function related to fine motor skills in individuals with Huntington’s disease (HD) 
• Timeline: 3-4 study visits over the course of 7 weeks and 3 Neurologic Music Therapy sessions per week for 5 weeks
• Intervention: Neurologic Music Therapy (can be done at the office of a music therapist, virtually, or in home depending on location)
• ClinicalTrials.gov Identifier: NCT03049033  
• Key Eligibility Criteria: age 30-85 years old, diagnosis: HD, have some difficulties with fine motor skills (such as buttoning, cutting your food, or typing on a keyboard)
  

Dystonia Coalition Projects-3 (20-0290)  

• Investigator: Jeanne Feuerstein, MD 
• Purpose: This research includes four related projects each having different but overlapping goals: (1) learn about how dystonia may progress over time and what causes dystonia (Natural History project), (2) develop tools to measure the severity of symptoms objectively (Objective Measures project), (3) create a collection of blood samples for analysis (Biobank project), and (4) develop an app to monitor symptom severity (optional Patient-Centered Outcomes project)
• Website: Dystonia Coalition 
• Key Eligibility Criteria: age 18+ years old, diagnosis: any isolated focal, segmental, multifocal, generalized, or hemi-dystonia, for optional Patient-Centered Outcomes project: receiving Botulinum neurotoxin (BoNT) treatments as part of regular treatment plan
  

FA-COMS (18-1641)  

• Investigator: Trevor Hawkins, MD 
• Purpose: to learn more about Friedreich ataxia (FRDA) progression and to measure clinical and biochemical changes over time 
• Timeline: annual visits 
• ClinicalTrials.gov Identifier: NCT03090789 
• Key Eligibility Criteria: age 18+ years old, diagnosis: Friedreich ataxia (FRDA)
  

Michael J. Fox Foundation PPMI 2.0 (20-1204) 

• Investigator: Michelle Fullard, MD, MSCE  
• Purpose: to continue to obtain information from people with and without Parkinson’s disease (PD) so that researchers may better understand how PD progresses, in order to inform better treatments 
• Timeline: 2 visits annually for up to 7 years 
• ClinicalTrials.gov Identifier: NCT04477785 
• Key Eligibility Criteria: have NOT been diagnosed with PD, do NOT have a first degree relative with PD and age: 30+ years old OR have NOT been diagnosed with PD, have a first degree relative with PD and age: 60+ years old
  

Cytokine Observational Study (18-1356)  

• Investigator:  Maureen Leehey, MD, FAAN  
• Purpose: to learn more about the level of inflammatory and other markers in the blood of patients with PD, ET, and healthy volunteers  
• Timeline: one time blood draw   
• Key Eligibility Criteria: have NOT been diagnosed with  Parkinson’s disease (PD) or essential tremor (ET), age: 60-75 years old